GlassScriptPhysician profile
Kartika Reddy
NPI 1548584311
$9,027.19
in general payments reported to CMS, 2019-2025
27 companies · $367 in 2025
The $367 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $971 · 2020: $1,323 · 2021: $1,956 · 2022: $1,694 · 2023: $2,196 · 2024: $521 · 2025: $367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,026 · Education: $57.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,025.97 |
| Education | $57.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,555.64 | 2019-2025 | |
| Janssen Biotech, INC. | $1,801.32 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $1,383.42 | 2019-2024 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $642.35 | 2019-2024 | Xifaxan, Trulance |
| Genzyme Corporation | $443.03 | 2022-2025 | |
| Pfizer INC. | $383.23 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $284.20 | 2020-2023 | Linzess |
| Ardelyx, INC. | $239.67 | 2022-2025 | Ibsrela |
| Celgene Corporation | $238.92 | 2021-2023 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $207.54 | 2022-2023 | Zeposia |
| Ferring Pharmaceuticals INC. | $186.82 | 2019-2023 | Rebyota, Cimzia |
| Braintree Laboratories, INC. | $81.56 | 2019-2023 | Suflave |
| Gilead Sciences, INC. | $79.96 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $69.05 | 2019-2023 | Dificid |
| Madrigal Pharmaceuticals | $59.12 | 2025 | Rezdiffra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $47.34 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $41.71 | 2020-2021 | |
| Allergan, INC. | $40.53 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $36.40 | 2022-2023 | Dupixent |
| Lilly USA, LLC | $34.17 | 2025 | Omvoh |
| Redhill Biopharma INC. | $31.31 | 2020-2022 | |
| Shionogi INC | $31.02 | 2019 | |
| Medtronic, INC. | $28.67 | 2023-2024 | Interstim, Gi Genius |
| Mauna Kea Technologies, INC. | $26.00 | 2024 | |
| Daiichi Sankyo INC. | $20.67 | 2022 | |
| Organon LLC | $19.10 | 2021-2023 | Hadlima, Renflexis |
| Celltrion USA INC. | $14.44 | 2024 | Zymfentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kartika Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.